3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Uterine Cervical Neoplasms
7
Papillomavirus Infections
6
Neoplasms
5
Breast Neoplasms
4
Uterine Cervical Dysplasia
3
Melanoma
3
Lung Neoplasms
3
Herpes Zoster
3
Condylomata Acuminata
3
Vulvar Neoplasms
2
Prostatic Neoplasms
2
Influenza, Human
2
Anus Neoplasms
2
Wilms Tumor
1
Whooping Cough
1
Waldenstrom Macroglobulinemia
1
Vaginal Neoplasms
1
Tetanus
1
Squamous Cell Carcinoma of Head and Neck
1
Spondylitis, Ankylosing
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rheumatic Diseases
1
Recurrence
1
Psoriasis
1
Persistent Infection
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Neoplasms, Glandular and Epithelial
1
Nasopharyngeal Neoplasms
1
Interventions
Rituximab
52
Cyclophosphamide
42
fludarabine phosphate
41
Peripheral Blood Stem Cell Transplantation
41
Whole-Body Irradiation
26
Mycophenolic Acid
25
Cyclosporine
21
Bortezomib
21
Dexamethasone
19
Busulfan
18
Tacrolimus
17
Etoposide
17
Filgrastim
15
Antilymphocyte Serum
14
Methotrexate
13
Melphalan
13
ibrutinib
12
Radiotherapy
11
Calcium Dobesilate
9
Sirolimus
8
Lenalidomide
8
Cyclosporins
8
Methylprednisolone
7
Flow Cytometry
7
Everolimus
7
Carboplatin
7
ibritumomab tiuxetan
6
zanubrutinib
5
fludarabine
5
Transplantation
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Waldenstrom Macroglobulinemia
×
Vaccines
×
Clear all
NCT02566265
2019-01-30
SHIVERING 2
Yale University
Phase 2
Completed
122 enrolled
10 charts